Literature DB >> 28641476

Direct medical costs of accidental falls for adults with transfemoral amputations.

Benjamin Mundell1, Hilal Maradit Kremers1, Sue Visscher1, Kurtis Hoppe1, Kenton Kaufman1.   

Abstract

BACKGROUND: Active individuals with transfemoral amputations are provided a microprocessor-controlled knee with the belief that the prosthesis reduces their risk of falling. However, these prostheses are expensive and the cost-effectiveness is unknown with regard to falls in the transfemoral amputation population. The direct medical costs of falls in adults with transfemoral amputations need to be determined in order to assess the incremental costs and benefits of microprocessor-controlled prosthetic knees.
OBJECTIVE: We describe the direct medical costs of falls in adults with a transfemoral amputation. STUDY
DESIGN: This is a retrospective, population-based, cohort study of adults who underwent transfemoral amputations between 2000 and 2014.
METHODS: A Bayesian structural time series approach was used to estimate cost differences between fallers and non-fallers.
RESULTS: The mean 6-month direct medical costs of falls for six hospitalized adults with transfemoral amputations was US$25,652 (US$10,468, US$38,872). The mean costs for the 10 adults admitted to the emergency department was US$18,091 (US$-7,820, US$57,368).
CONCLUSION: Falls are expensive in adults with transfemoral amputations. The 6-month costs of falls resulting in hospitalization are similar to those reported in the elderly population who are also at an increased risk of falling. Clinical relevance Estimates of fall costs in adults with transfemoral amputations can provide policy makers with additional insight when determining whether or not to cover a prescription for microprocessor-controlled prosthetic knees.

Keywords:  Amputation; Bayesian analysis; cost analysis

Mesh:

Year:  2017        PMID: 28641476     DOI: 10.1177/0309364617704804

Source DB:  PubMed          Journal:  Prosthet Orthot Int        ISSN: 0309-3646            Impact factor:   1.895


  7 in total

1.  Using Clinical Balance Tests to Assess Fall Risk among Established Unilateral Lower Limb Prosthesis Users: Cutoff Scores and Associated Validity Indices.

Authors:  Andrew Sawers; Brian J Hafner
Journal:  PM R       Date:  2019-05-03       Impact factor: 2.298

2.  The Kenevo microprocessor-controlled prosthetic knee compared with non-microprocessor-controlled knees in individuals older than 65 years in Sweden: A cost-effectiveness and budget-impact analysis.

Authors:  Alexander Kuhlmann; Kerstin Hagberg; Ilka Kamrad; Nerrolyn Ramstrand; Susanne Seidinger; Hans Berg
Journal:  Prosthet Orthot Int       Date:  2022-05-03       Impact factor: 1.672

3.  Factors associated with the likelihood of fall-related injury among people with lower limb loss.

Authors:  Stanford Chihuri; Christopher Kevin Wong
Journal:  Inj Epidemiol       Date:  2018-11-12

4.  Can microprocessor knees reduce the disparity in trips and falls risks between above and below knee prosthesis users?

Authors:  Michael McGrath; Laura A Gray; Beata Rek; Kate C Davies; Zoe Savage; Jane McLean; Alison Stenson; Saeed Zahedi
Journal:  PLoS One       Date:  2022-09-02       Impact factor: 3.752

5.  Factors leading to falls in transfemoral prosthesis users: a case series of sound-side stumble recovery responses.

Authors:  Maura E Eveld; Shane T King; Karl E Zelik; Michael Goldfarb
Journal:  J Neuroeng Rehabil       Date:  2022-09-23       Impact factor: 5.208

Review 6.  Economic benefits of microprocessor controlled prosthetic knees: a modeling study.

Authors:  Christine Chen; Mark Hanson; Ritika Chaturvedi; Soeren Mattke; Richard Hillestad; Harry H Liu
Journal:  J Neuroeng Rehabil       Date:  2018-09-05       Impact factor: 4.262

7.  Cost-effectiveness and budget impact of the microprocessor-controlled knee C-Leg in transfemoral amputees with and without diabetes mellitus.

Authors:  Alexander Kuhlmann; Henning Krüger; Susanne Seidinger; Andreas Hahn
Journal:  Eur J Health Econ       Date:  2020-01-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.